Efficacy of Majoon Chobchini versus Majoon Ushba with Roghane Surkh in Post Chikungunya Arthritis - A Randomized Single Blind Comparative Clinical Trial

Introduction Post Chikungunya Arthritis PCA is a prevalent and debilitating condition following Chikungunya fever characterized by persistent arthralgia and joint-related symptoms. While conventional treatments include non-steroidal anti-inflammatory drugs NSAIDs and disease-modifying antirheumatic drugs DMARDs they are associated with various side effects. In Unani medicine the use of Majoon Chobchini Majoon Ushba and Roghane Surkh has been recommended for PCA management potentially offering a safer alternative.Methods This randomized single-blind comparative clinical trial was conducted over one and half years involved 99 PCA patients aged 18-50 years. Patients were randomly assigned to either Group A Majoon Chobchini with Roghane Surkh or Group B Majoon Ushba with Roghane Surkh. Disease activity and inflammatory markers were assessed using Disease Activity Score DAS 28 Clinical Disease Activity Index CDAI Health Assessment Questionnaire HAQ and C-reactive protein CRP levels. Safety parameters including hematological and hepato and renal biochemical profiles were monitored. Statistical analysis was performed using appropriate tests.Results Both Group A and Group B showed significant improvements in DAS 28 scores P lt0.001 HAQ scores P lt0.001 CDAI scores P lt0.001 and CRP levels P lt0.001 after four weeks treatment with no significant differences between the groups. Safety parameters remained stable indicating the safety of both Majoon Chobchini and Majoon Ushba.Conclusion Majoon Chobchini and Majoon Ushba with Roghane Surkh demonstrated comparable efficacy in reducing the symptoms of PCA as evidenced by improvements in disease activity and inflammation parameters. Both interventions exhibited a favorable safety profile. These findings suggest the potential of these Unani formulations as alternative therapeutic options for PCA management warranting further research and clinical exploration.